Hepatic Cytochrome P450 Enzymatic System Interaction With Platelet Function and Cardiovascular...

Platelets are small, anucleate particles derived from bone marrow megakaryocytes that circulate in the blood and are central to hemostasis, atherothrombosis, and post-angioplasty coronary restenosis. Initially thought to involve a simple process of platelet adhesion, activation, and aggregation, recent insights reveal an important interplay with genetics and other organ systems, especially in the setting of antiplatelet drug therapy. Interaction involving the hepatic cytochrome P450 enzymes, which regulate drug metabolism, and genetic variation in those enzymes affecting drug response, underscores the liver's role in modulating platelet function by attenuating circulating active drug metabolites with eventual cardiovascular implications. Circulating adhesive proteins such as von Willebrand Factor and fibronectin also significantly regulate platelet aggregation, a process that is further influenced by varying shear conditions within the vascular system. The efficacy of antiplatelet therapies can be attenuated by such individual genetic variation, which can affect multiple cellular pathways involved not only in drug metabolism and clearance but also the drug target itself. Identifying these genetic differences allows for tailored therapy, enhancing treatment outcomes and minimizing adverse effects. Genetic variation, particularly in the CYP2C19 gene, influences individual responses to the most commonly used antiplatelet drug other than aspirin, clopidogrel, with certain variants leading to reduced drug metabolism and antiplatelet effects. Therefore, genotype-guided antiplatelet therapy has emerged as a promising approach to reduce ischemic events and minimize bleeding events. This personalized strategy requires an understanding of genetic variation, drug-gene interaction, and the liver's role in impacting platelet function, the coagulation system, and cardiovascular systems.